Toward a transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects: Challenges, opportunities, and next steps
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Toward a transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects : Challenges, opportunities, and next steps. / Petersen, Cecilia S; Miskowiak, Kamilla W.
In: CNS Spectrums, Vol. 26, No. 4, 2021, p. 333-337.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Toward a transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects
T2 - Challenges, opportunities, and next steps
AU - Petersen, Cecilia S
AU - Miskowiak, Kamilla W
PY - 2021
Y1 - 2021
N2 - Cognitive impairment has emerged as a key treatment priority in neuropsychiatric disorders. However, there is a lack of treatments with solid and lasting efficacy on cognition. A neurocircuitry-based biomarker model of pro-cognitive effects is critically needed to select among new candidate treatments. In a recent review of functional magnetic resonance imaging (fMRI) studies in mood disorders, we found that cognitive impairments are consistently accompanied by aberrant (hypo- and hyper-) activity in the dorsal prefrontal cortex (PFC) and the default mode network (DMN), and that activity change in these regions commonly occurs with cognitive improvements. Here, we (i) review the putative model from our recent review article, which explains the discrepant findings regarding the direction of aberrant dorsal PFC activity and treatment-related activity change in mood disorders. Inspired by the Research Domain Criteria project, we do this in order to (ii) examine whether a similar pattern of activity change occurs across distinct neuropsychiatric disorders and thereby provides a common biomarker for pro-cognitive effects. Lastly, we (iii) discuss whether dorsal PFC and DMN target engagement is a putative transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects, and (iv) outline the necessary next steps to address this question.
AB - Cognitive impairment has emerged as a key treatment priority in neuropsychiatric disorders. However, there is a lack of treatments with solid and lasting efficacy on cognition. A neurocircuitry-based biomarker model of pro-cognitive effects is critically needed to select among new candidate treatments. In a recent review of functional magnetic resonance imaging (fMRI) studies in mood disorders, we found that cognitive impairments are consistently accompanied by aberrant (hypo- and hyper-) activity in the dorsal prefrontal cortex (PFC) and the default mode network (DMN), and that activity change in these regions commonly occurs with cognitive improvements. Here, we (i) review the putative model from our recent review article, which explains the discrepant findings regarding the direction of aberrant dorsal PFC activity and treatment-related activity change in mood disorders. Inspired by the Research Domain Criteria project, we do this in order to (ii) examine whether a similar pattern of activity change occurs across distinct neuropsychiatric disorders and thereby provides a common biomarker for pro-cognitive effects. Lastly, we (iii) discuss whether dorsal PFC and DMN target engagement is a putative transdiagnostic neurocircuitry-based biomarker model for pro-cognitive effects, and (iv) outline the necessary next steps to address this question.
KW - Faculty of Social Sciences
KW - cognitive impairment
KW - fMRI
KW - neural underpinnings
KW - dorsal prefrontal cortex
KW - default mode network
KW - neurocircuitry-based biomarker model
U2 - 10.1017/S1092852920000061
DO - 10.1017/S1092852920000061
M3 - Journal article
C2 - 32122432
VL - 26
SP - 333
EP - 337
JO - CNS Spectrums
JF - CNS Spectrums
SN - 1092-8529
IS - 4
ER -
ID: 256075035